- Home
- MMI vs XNCR Comparison
MMI vs XNCR Comparison
Compare MMI & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMI
- XNCR
- Stock Information
- Founded
- MMI 1971
- XNCR 1997
- Country
- MMI United States
- XNCR United States
- Employees
- MMI N/A
- XNCR N/A
- Industry
- MMI Real Estate
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- MMI Finance
- XNCR Health Care
- Exchange
- MMI Nasdaq
- XNCR Nasdaq
- Market Cap
- MMI 1.6B
- XNCR 1.5B
- IPO Year
- MMI 2013
- XNCR 2013
- Fundamental
- Price
- MMI $40.62
- XNCR $23.85
- Analyst Decision
- MMI Sell
- XNCR Strong Buy
- Analyst Count
- MMI 1
- XNCR 8
- Target Price
- MMI $30.00
- XNCR $35.50
- AVG Volume (30 Days)
- MMI 89.1K
- XNCR 553.6K
- Earning Date
- MMI 11-08-2024
- XNCR 11-06-2024
- Dividend Yield
- MMI 1.25%
- XNCR N/A
- EPS Growth
- MMI N/A
- XNCR N/A
- EPS
- MMI N/A
- XNCR N/A
- Revenue
- MMI $622,225,000.00
- XNCR $85,164,000.00
- Revenue This Year
- MMI N/A
- XNCR N/A
- Revenue Next Year
- MMI $26.79
- XNCR $86.53
- P/E Ratio
- MMI N/A
- XNCR N/A
- Revenue Growth
- MMI N/A
- XNCR N/A
- 52 Week Low
- MMI $29.93
- XNCR $15.31
- 52 Week High
- MMI $44.24
- XNCR $26.84
- Technical
- Relative Strength Index (RSI)
- MMI 54.56
- XNCR 68.48
- Support Level
- MMI $39.77
- XNCR $22.60
- Resistance Level
- MMI $41.53
- XNCR $23.86
- Average True Range (ATR)
- MMI 1.15
- XNCR 0.81
- MACD
- MMI -0.05
- XNCR 0.03
- Stochastic Oscillator
- MMI 50.19
- XNCR 90.46
About MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a leading national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.